Michal Mark Danieli
Research Subjects
Michal Mark Danieli has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ory Wiesel
Baruch Padeh-Tzafon Medical Center, Poriya 1528001, Israel
2 shared publications - Adi Laser-Azogui
EARLY O.M. Ltd., Netanya 4250363, Israel
1 shared publication - Alaa Awad
Baruch Padeh—Tzafon Medical Center, Affiliated with the Azrieli Faculty of Medicine, Bar-Ilan University, Zefad 1528001, Israel
1 shared publication - Amit Katz
Head of Thoracic Surgery, Rambam Health Care Campus, P.O. Box 9602, Haifa 3109601, Israel
1 shared publication - Inbal Nir-Ziv
Early OM, 4 Meir Ariel St., Natanya 4253063, Israel
1 shared publication - Iris Kamer
Institute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan 5262000, Israel
1 shared publication
Latest Publications
- Open Access
- 16 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6164
The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.
- 16 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6164
Open AccessThe Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.
- Open Access
- 6 June 2023
- Published by MDPI AG in Biosensors
- Vol. 13 (6) , 627
A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection
Lung cancer is the leading cause of cancer-related mortality worldwide. Early detection is essential to achieving a better outcome and prognosis. Volatile organic compounds (VOCs) reflect alterations in the pathophysiology and body metabolism processes, as shown in various types of cancers. The biosensor platform (BSP) urine test uses animals’ unique, proficient, and accurate ability to scent lung cancer VOCs. The BSP is a testing platform for the binary (negative/positive) recognition of the signature VOCs of lung cancer by trained and qualified Long–Evans rats as biosensors (BSs). The results of the current double-blind study show high accuracy in lung cancer VOC recognition, with 93% sensitivity and 91% specificity. The BSP test is safe, rapid, objective and can be performed repetitively, enabling periodic cancer monitoring as well as an aid to existing diagnostic methods. The future implementation of such urine tests as routine screening and monitoring tools has the potential to significantly increase detection rate as well as curability rates with lower healthcare expenditure. This paper offers a first instructive clinical platform utilizing VOC’s in urine for detection of lung cancer using the innovative BSP to deal with the pressing need for an early lung cancer detection test tool.
- 6 June 2023
- Published by MDPI AG in Biosensors
- Vol. 13 (6) , 627
Open AccessA Novel Urine Test Biosensor Platform for Early Lung Cancer Detection
Lung cancer is the leading cause of cancer-related mortality worldwide. Early detection is essential to achieving a better outcome and prognosis. Volatile organic compounds (VOCs) reflect alterations in the pathophysiology and body metabolism processes, as shown in various types of cancers. The biosensor platform (BSP) urine test uses animals’ unique, proficient, and accurate ability to scent lung cancer VOCs. The BSP is a testing platform for the binary (negative/positive) recognition of the signature VOCs of lung cancer by trained and qualified Long–Evans rats as biosensors (BSs). The results of the current double-blind study show high accuracy in lung cancer VOC recognition, with 93% sensitivity and 91% specificity. The BSP test is safe, rapid, objective and can be performed repetitively, enabling periodic cancer monitoring as well as an aid to existing diagnostic methods. The future implementation of such urine tests as routine screening and monitoring tools has the potential to significantly increase detection rate as well as curability rates with lower healthcare expenditure. This paper offers a first instructive clinical platform utilizing VOC’s in urine for detection of lung cancer using the innovative BSP to deal with the pressing need for an early lung cancer detection test tool.